Myriad Genetics Stock
Price
Target price
€4.30
€4.30
1.900%
0.08
1.900%
€12.32
05.06.25 / Stuttgart Stock Exchange
WKN: 897518 / Symbol: MYGN / Name: Myriad Genetics / Stock / Healthcare Equipment & Supplies / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Myriad Genetics Stock
Myriad Genetics gained 1.900% today.
Our community is currently high on Myriad Genetics with 9 Buy predictions and 3 Sell predictions.
With a target price of 12 € there is potential for a 179.07% increase which would mean more than doubling the current price of 4.3 € for Myriad Genetics.
So far the community has only identified positive things for Myriad Genetics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Myriad Genetics in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Myriad Genetics | 1.900% | 18.785% | -32.813% | -79.126% | -66.142% | -76.098% | -69.930% |
| Healthequity Inc. | 3.170% | 10.795% | 23.418% | 26.623% | 7.143% | 63.866% | 87.500% |
| Omnicell Inc. | -1.470% | 1.515% | 0.752% | -2.190% | -35.577% | -73.200% | -54.576% |
| Bruker Corp. | 2.460% | 3.959% | -3.085% | -42.488% | -39.398% | - | - |
Comments
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $12.50 to $9.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $14.00 to $8.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $10.00 price target on the stock, down previously from $19.00.
Show more
Ratings data for MYGN provided by MarketBeat